The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Clinical factors
Inflammatory indices
Metastatic castration-resistant prostate cancer
Neutrophil-to-lymphocyte ratio
[223Ra]RaCl2
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
03
06
2021
accepted:
29
08
2021
pubmed:
7
9
2021
medline:
16
3
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([ Baseline neutrophil-to-lymphocyte ratio (NLR), derived NLR (donor), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), Eastern Cooperative Oncology Group performance status (ECOG PS), Gleason score (GS) group, number of bone metastases, prostate-specific antigen (PSA), alkaline phosphatase (ALP), line of therapy, previous chemotherapy, and the presence of lymphadenopathies were collected from seven Italian centers between 2013 and 2020. Lab and clinical data were assessed in correlation with the overall survival (OS). Inflammatory indices were then included separately in the multivariable analyses with the prognostic clinical factors. The model with the highest discriminative ability (c-index) was chosen to develop the BIO-Ra score. Five hundred and nineteen mCRPC patients (median OS: 19.9 months) were enrolled. Higher NLR, dNLR, PLR, and SII and lower LMR predicted worse OS (all with a p < 0.001). The multivariable model including NLR, ECOG PS, number of bone metastases, ALP, and PSA (c-index: 0.724) was chosen to develop the BIO-Ra score. Using the Schneeweiss scoring system, the BIO-Ra score identified three prognostic groups (36%, 27.3%, and 36.6% patients, respectively) with distinct median OS (31, 26.6, and 9.6 months, respectively; hazard ratio: 1.62, p = 0.008 for group 2 vs. 1 and 5.77, p < 0.001 for group 3 vs. 1). The BIO-Ra score represents an easy and widely applicable tool for the prognostic stratification of mCRPC patients treated with [
Identifiants
pubmed: 34486070
doi: 10.1007/s00259-021-05550-6
pii: 10.1007/s00259-021-05550-6
pmc: PMC8803683
doi:
Substances chimiques
Radium-223
8BR2SOL3L1
Radium
W90AYD6R3Q
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1063-1074Informations de copyright
© 2021. The Author(s).
Références
Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004;91:718–29.
pubmed: 14991763
McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, et al. The clinical and economic impacts of skeletal-related events among Medicare enrollees with prostate cancer metastatic to bone. Oncologist. 2016;21:320–6.
pubmed: 26865591
pmcid: 4786354
Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1–14.
pubmed: 23326203
pmcid: 3544343
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
pubmed: 23863050
Kluetz PG, Pierce W, Maher VE, Zhang H, Tang S, Song P, et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2014;20:9–14.
pubmed: 24190979
Parikh S, Murray L, Kenning L, Bottomley D, Din O, Dixit S, et al. Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer. Clin Oncol (R Coll Radiol). 2018;30:548–55.
Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, et al. Factors associated with survival following radium-223 treatment for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15:e969–75.
pubmed: 28545997
Frantellizzi V, Farcomeni A, Follacchio GA, Pacilio M, Pellegrini R, Pani R, et al. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride. Ann Nucl Med. 2018;32:142–8.
pubmed: 29285670
Den RB, George D, Pieczonka C, McNamara M. Ra-223 treatment for bone metastases in castrate-resistant prostate cancer: practical management issues for patient selection. Am J Clin Oncol. 2019;42:399–406.
pubmed: 30844849
pmcid: 6445613
EMA. EMA restricts use of prostate cancer medicine XOFIGO. Available online: https://www.ema.europa.eu/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo (accessed on 8 May 2021).
Kuppen MC, Westgeest HM, van der Doelen MJ, van den Eertwegh AJ, Coenen JL, Aben KK, et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncol. 2020;16:1371–84.
pubmed: 32469606
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
pubmed: 21376230
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.
pubmed: 24875653
Liu R, Zheng S, Yuan Q, Zhu P, Li B, Lin Q, et al. The prognostic significance of combined pretreatment fibrinogen and neutrophil-lymphocyte ratio in various cancers: a systematic review and meta-analysis. Dis Markers. 2020;2020:4565379.
pubmed: 33376559
pmcid: 7746466
Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18:360.
pubmed: 33213430
pmcid: 7678319
Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 2020;23:220–31.
pubmed: 32034294
Man YN, Chen YF. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel. Int Urol Nephrol. 2019;51:2189–99.
pubmed: 31456101
Bauckneht M, Rebuzzi SE, Signori A, Donegani MI, Murianni V, Miceli A, et al. The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with radium-223: a proof of concept study. Cancers (Basel). 2020;12:3213.
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:824–45.
pubmed: 29234845
Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–44.
pubmed: 10877287
Cattaneo M, Malighetti P, Spinelli D. Estimating receiver operative characteristic curves for time-dependent outcomes: the stroccurve package. Stand Genomic Sci. 2017;17:1015–23.
Liu X. Classification accuracy and cut point selection. Stat Med. 2012;31:2676–86.
pubmed: 22307964
Liu X, Jin Z. Optimal survival time-related cut-point with censored data. Stat Med. 2015;34:515–24.
pubmed: 25382379
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
StataCorp. Stata statistical software: release 16. College Station: StataCorp LLC; 2019.
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/ . Accessed 1 Jun 2021.
Mehta HB, Mehta V, Girman CJ, Adhikari D, Johnson ML. Regression coefficient-based scoring system should be used to assign weights to the risk index. J Clin Epidemiol. 2016;79:22–8.
pubmed: 27181564
Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28:1090–7.
pubmed: 28453701
pmcid: 5406754
Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195–202.
pubmed: 3334948
De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O’Sullivan JM, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019;30:1728–39.
pubmed: 31418764
pmcid: 6927314
McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, et al. Radium-223 use in clinical practice and variables associated with completion of therapy. Clin Genitourin Cancer. 2017;15:e289–98.
pubmed: 27651103
Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17:1306–16.
pubmed: 27473888
Naito M, Ukai R, Hashimoto K. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223. Cancer Rep (Hoboken). 2019;2:e1203.
Prelaj A, Rebuzzi SE, Buzzacchino F, Pozzi C, Ferrara C, Frantellizzi V, et al. Radium-223 in patients with metastatic castration-resistant prostate cancer: efficacy and safety in clinical practice. Oncol Lett. 2019;17:1467–76.
pubmed: 30675201
Maruzzo M, Basso U, Borsatti E, Evangelista L, Alongi F, Caffo O, et al. Results from a large, multicenter, retrospective analysis on radium223 use in metastatic castration-resistant prostate cancer (mCRPC) in the Triveneto Italian Region. Clin Genitourin Cancer. 2019;17:e187–94.
pubmed: 30448106
Parimi S, Tsang E, Alexander A, Mckenzie M, Bachand F, Sunderland K, et al. A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: factors associated with treatment completion. Can Urol Assoc J. 2017;11:350–5.
pubmed: 29382449
pmcid: 5963449
De Luca R, Costa RP, Tripoli V, Murabito A, Cicero G. the clinical efficacy of radium-223 for bone metastasis in patients with castration-resistant prostate cancer: an Italian clinical experience. Oncology. 2018;94:161–6.
pubmed: 29241166
Vidal M, Delgado A, Martinez C, Correa JJ, Durango IC. Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223. Int Braz J Urol. 2020;46:599–611.
pubmed: 32213206
pmcid: 7239273
Bauckneht M, Capitanio S, Donegani MI, Zanardi E, Miceli A, Murialdo R, et al. Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223. Cancers (Basel). 2019;12:31.
Filippi L, Spinelli GP, Chiaravalloti A, Schillaci O, Equitani F, Bagni O. Prognostic value of 18F-Choline PET/CT in Patients with metastatic castration-resistant prostate cancer treated with radium-223. Biomedicines. 2020;8:555.
pmcid: 7760591
Roque V, Jessop M, Pereira L, Gape P, Dizdarevic S, Sousa E, et al. Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response. Nucl Med Commun. 2019;40:588–96.
pubmed: 30908340
Frantellizzi V, Pani A, Ippoliti MD, Farcomeni A, Aloise I, Colosi M, et al. Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment. Radiol Oncol. 2019;54:40–7.
pubmed: 31855572
pmcid: 7087429
Bauckneht M, Bertagna F, Donegani MI, Durmo R, Miceli A, De Biasi V, et al. The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer Prostatic Dis. 2021. https://doi.org/10.1038/s41391-021-00391-8 .
doi: 10.1038/s41391-021-00391-8
pubmed: 34012060
pmcid: 8616756
Ricci M, Frantellizzi V, Bulzonetti N, De Vincentis G. Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature. Int J Radiat Biol. 2019;95:554–61.
pubmed: 30557063
Frantellizzi V, Monari F, Mascia M, Costa R, Rubini G, Spanu A, et al. Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with 223Radium-dichloride: a national multicenter study. Ann Nucl Med. 2020;34:772–80.
pubmed: 32654030
pmcid: 7515961
Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase. Int J Urol. 1997;4:572–5.
pubmed: 9477186
Saad F, Gillessen S, Heinrich D, Keizman D, O’Sullivan JM, Nilsson S, et al. Disease characteristics and completion of treatment in patients with metastatic castration-resistant prostate cancer treated with radium-223 in an international early access program. Clin Genitourin Cancer. 2019;17:348-355.e5.
pubmed: 31311763
van der Doelen MJ, Stockhaus A, Ma Y, Mehra N, Yachnin J, Gerritsen WR, et al. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05283-6 .
doi: 10.1007/s00259-021-05283-6
pubmed: 33686456
pmcid: 8426246